Nisa Investment Advisors LLC Sells 1,086 Shares of Axonics, Inc. (NASDAQ:AXNX)

Nisa Investment Advisors LLC trimmed its holdings in shares of Axonics, Inc. (NASDAQ:AXNX) by 68.9% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 490 shares of the company’s stock after selling 1,086 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Axonics were worth $30,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the stock. HighMark Wealth Management LLC increased its position in shares of Axonics by 200.0% during the third quarter. HighMark Wealth Management LLC now owns 525 shares of the company’s stock worth $29,000 after acquiring an additional 350 shares in the last quarter. Exchange Traded Concepts LLC bought a new position in Axonics during the 3rd quarter worth about $37,000. RiverPark Advisors LLC acquired a new stake in shares of Axonics in the 3rd quarter valued at about $58,000. C M Bidwell & Associates Ltd. lifted its holdings in shares of Axonics by 108.2% in the third quarter. C M Bidwell & Associates Ltd. now owns 1,270 shares of the company’s stock valued at $71,000 after purchasing an additional 660 shares in the last quarter. Finally, Covestor Ltd boosted its position in shares of Axonics by 40.8% during the third quarter. Covestor Ltd now owns 3,143 shares of the company’s stock worth $176,000 after buying an additional 911 shares during the period. 99.48% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have commented on AXNX. Royal Bank of Canada restated a “sector perform” rating and issued a $71.00 target price on shares of Axonics in a research note on Thursday, February 29th. Needham & Company LLC reiterated a “hold” rating on shares of Axonics in a research note on Wednesday, January 17th. CL King restated a “neutral” rating on shares of Axonics in a report on Friday, January 12th. SVB Leerink reiterated a “market perform” rating and set a $71.00 target price on shares of Axonics in a report on Friday, January 12th. Finally, Truist Financial restated a “hold” rating and issued a $71.00 price target (down from $73.00) on shares of Axonics in a research note on Friday, January 12th. Eight research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, Axonics has an average rating of “Hold” and a consensus target price of $70.73.

Insider Transactions at Axonics

In related news, CFO Kari Leigh Keese sold 3,489 shares of Axonics stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $67.74, for a total transaction of $236,344.86. Following the completion of the sale, the chief financial officer now directly owns 43,323 shares of the company’s stock, valued at approximately $2,934,700.02. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Axonics news, CEO Raymond W. Cohen sold 35,161 shares of the stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $67.74, for a total transaction of $2,381,806.14. Following the transaction, the chief executive officer now owns 188,835 shares in the company, valued at approximately $12,791,682.90. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Kari Leigh Keese sold 3,489 shares of Axonics stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $67.74, for a total transaction of $236,344.86. Following the completion of the sale, the chief financial officer now owns 43,323 shares of the company’s stock, valued at $2,934,700.02. The disclosure for this sale can be found here. Insiders sold a total of 65,837 shares of company stock worth $4,459,798 over the last quarter. Company insiders own 1.85% of the company’s stock.

Axonics Price Performance

Shares of Axonics stock opened at $66.84 on Tuesday. Axonics, Inc. has a 1 year low of $47.59 and a 1 year high of $69.68. The company has a market capitalization of $3.41 billion, a price-to-earnings ratio of -514.11 and a beta of 0.56. The business has a fifty day simple moving average of $68.00 and a two-hundred day simple moving average of $62.59.

Axonics (NASDAQ:AXNX) last announced its earnings results on Wednesday, February 28th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.06 by $0.07. The business had revenue of $109.70 million during the quarter, compared to the consensus estimate of $107.33 million. Axonics had a negative net margin of 1.66% and a negative return on equity of 1.00%. Axonics’s revenue was up 27.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.01 EPS. As a group, equities analysts anticipate that Axonics, Inc. will post 0.32 earnings per share for the current fiscal year.

Axonics Profile

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.